Recent studies that patients bearing IDH1/2 mutations in gliomas, cholangiocarcinomas, and to some extent the AML, experience a longer median survival than their wildtype counterparts, and they also show many favorable responses to radiotherapy and chemotherapy has prompted a new thinking on IDH1 mutations. Here, IDH1 is linked to glioma.